APO Research
Talk to an analyst

APO RESEARCH · REPORT

Virus like Particle (VLP) Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Virus like Particle (VLP) Vaccines Market Outlook and Growth Opportunities 2026

29 December 2025197 pages

Choose your research edition.

Industry ResearchVirus like Particle (VLP) Vaccines Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Virus like Particle (VLP) Vaccines Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Virus like Particle (VLP) Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Virus like Particle (VLP) Vaccines Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Virus like Particle (VLP) Vaccines Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Virus like Particle (VLP) Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Virus like Particle (VLP) Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Virus like Particle (VLP) Vaccines market include WuXi Biologics, Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., VBI Vaccines Inc, Premas Biotech, Creative Diagnostics and Creative Biostructure, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Virus like Particle (VLP) Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Virus like Particle (VLP) Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Virus like Particle (VLP) Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Virus like Particle (VLP) Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Virus like Particle (VLP) Vaccines Segment by Company

WuXi Biologics

Junshi Biosciences

Luye Pharma Group

Chengdu Kanghua Biological Products Co., Ltd.

Shanghai Bovax Biotechnology Co., Ltd.

VBI Vaccines Inc

Premas Biotech

Creative Diagnostics

Creative Biostructure

Coriolis

Charles River Laboratories

BioAgilytix

AstraZeneca Group (Icosavax)

Virus like Particle (VLP) Vaccines Segment by Type

Prophylactic Vaccine

Therapeutic Vaccine

Virus like Particle (VLP) Vaccines Segment by Application

Human Papillomavirus (HPV)

Hepatitis E Virus (HEV)

Hepatitis B Virus (HBV)

Other

Virus like Particle (VLP) Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Virus like Particle (VLP) Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Virus like Particle (VLP) Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Virus like Particle (VLP) Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Virus like Particle (VLP) Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus like Particle (VLP) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Virus like Particle (VLP) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus like Particle (VLP) Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Virus like Particle (VLP) Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Virus like Particle (VLP) Vaccines industry.

Chapter 3: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Virus like Particle (VLP) Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Virus like Particle (VLP) Vaccines Industry Trends Table 2. Virus like Particle (VLP) Vaccines Industry Drivers Table 3. Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges Table 4. Virus like Particle (VLP) Vaccines Industry Restraints Table 5. Global Virus like Particle (VLP) Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Virus like Particle (VLP) Vaccines Revenue Share by Company (2021-2026) Table 7. Global Virus like Particle (VLP) Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Virus like Particle (VLP) Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Virus like Particle (VLP) Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Virus like Particle (VLP) Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Virus like Particle (VLP) Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Virus like Particle (VLP) Vaccines Company, Product Type & Application Table 13. Global Virus like Particle (VLP) Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Virus like Particle (VLP) Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Prophylactic Vaccine Table 18. Significant Companies of Therapeutic Vaccine Table 19. Global Virus like Particle (VLP) Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Virus like Particle (VLP) Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Virus like Particle (VLP) Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Virus like Particle (VLP) Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Virus like Particle (VLP) Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Virus like Particle (VLP) Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Virus like Particle (VLP) Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Virus like Particle (VLP) Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Virus like Particle (VLP) Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Virus like Particle (VLP) Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Human Papillomavirus (HPV) Table 30. Significant Companies of Hepatitis E Virus (HEV) Table 31. Significant Companies of Hepatitis B Virus (HBV) Table 32. Significant Companies of Other Table 33. Global Virus like Particle (VLP) Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Virus like Particle (VLP) Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Virus like Particle (VLP) Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Virus like Particle (VLP) Vaccines Sales Volume Share by Application (2021-2026) Table 37. Global Virus like Particle (VLP) Vaccines Sales Volume Share by Application (2027-2032) Table 38. Global Virus like Particle (VLP) Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Virus like Particle (VLP) Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Virus like Particle (VLP) Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Virus like Particle (VLP) Vaccines Sales Value Share by Application (2021-2026) Table 42. Global Virus like Particle (VLP) Vaccines Sales Value Share by Application (2027-2032) Table 43. Global Virus like Particle (VLP) Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Virus like Particle (VLP) Vaccines Sales by Region (2021-2026) & (K Units) Table 45. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region (2021-2026) Table 46. Global Virus like Particle (VLP) Vaccines Sales by Region (2027-2032) & (K Units) Table 47. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region (2027-2032) Table 48. Global Virus like Particle (VLP) Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Virus like Particle (VLP) Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Virus like Particle (VLP) Vaccines Sales Value Share by Region (2021-2026) Table 51. Global Virus like Particle (VLP) Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Virus like Particle (VLP) Vaccines Sales Value Share by Region (2027-2032) Table 53. Global Virus like Particle (VLP) Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Virus like Particle (VLP) Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Virus like Particle (VLP) Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Virus like Particle (VLP) Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 58. Global Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2026) Table 59. Global Virus like Particle (VLP) Vaccines Sales by Country (2027-2032) & (K Units) Table 60. Global Virus like Particle (VLP) Vaccines Sales Market Share by Country (2027-2032) Table 61. Global Virus like Particle (VLP) Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Virus like Particle (VLP) Vaccines Sales Value Market Share by Country (2021-2026) Table 63. Global Virus like Particle (VLP) Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Virus like Particle (VLP) Vaccines Sales Value Market Share by Country (2027-2032) Table 65. WuXi Biologics Company Information Table 66. WuXi Biologics Business Overview Table 67. WuXi Biologics Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio Table 69. WuXi Biologics Recent Development Table 70. Junshi Biosciences Company Information Table 71. Junshi Biosciences Business Overview Table 72. Junshi Biosciences Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio Table 74. Junshi Biosciences Recent Development Table 75. Luye Pharma Group Company Information Table 76. Luye Pharma Group Business Overview Table 77. Luye Pharma Group Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio Table 79. Luye Pharma Group Recent Development Table 80. Chengdu Kanghua Biological Products Co., Ltd. Company Information Table 81. Chengdu Kanghua Biological Products Co., Ltd. Business Overview Table 82. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio Table 84. Chengdu Kanghua Biological Products Co., Ltd. Recent Development Table 85. Shanghai Bovax Biotechnology Co., Ltd. Company Information Table 86. Shanghai Bovax Biotechnology Co., Ltd. Business Overview Table 87. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio Table 89. Shanghai Bovax Biotechnology Co., Ltd. Recent Development Table 90. VBI Vaccines Inc Company Information Table 91. VBI Vaccines Inc Business Overview Table 92. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio Table 94. VBI Vaccines Inc Recent Development Table 95. Premas Biotech Company Information Table 96. Premas Biotech Business Overview Table 97. Premas Biotech Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio Table 99. Premas Biotech Recent Development Table 100. Creative Diagnostics Company Information Table 101. Creative Diagnostics Business Overview Table 102. Creative Diagnostics Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio Table 104. Creative Diagnostics Recent Development Table 105. Creative Biostructure Company Information Table 106. Creative Biostructure Business Overview Table 107. Creative Biostructure Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio Table 109. Creative Biostructure Recent Development Table 110. Coriolis Company Information Table 111. Coriolis Business Overview Table 112. Coriolis Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Coriolis Virus like Particle (VLP) Vaccines Product Portfolio Table 114. Coriolis Recent Development Table 115. Charles River Laboratories Company Information Table 116. Charles River Laboratories Business Overview Table 117. Charles River Laboratories Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio Table 119. Charles River Laboratories Recent Development Table 120. BioAgilytix Company Information Table 121. BioAgilytix Business Overview Table 122. BioAgilytix Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio Table 124. BioAgilytix Recent Development Table 125. AstraZeneca Group (Icosavax) Company Information Table 126. AstraZeneca Group (Icosavax) Business Overview Table 127. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio Table 129. AstraZeneca Group (Icosavax) Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Virus like Particle (VLP) Vaccines Distributors List Table 133. Virus like Particle (VLP) Vaccines Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Virus like Particle (VLP) Vaccines Product Image Figure 2. Global Virus like Particle (VLP) Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Virus like Particle (VLP) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Virus like Particle (VLP) Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Virus like Particle (VLP) Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Virus like Particle (VLP) Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Prophylactic Vaccine Image Figure 10. Therapeutic Vaccine Image Figure 11. Global Virus like Particle (VLP) Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Virus like Particle (VLP) Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Virus like Particle (VLP) Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Virus like Particle (VLP) Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Virus like Particle (VLP) Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Virus like Particle (VLP) Vaccines Sales Value Share by Type (2021-2032) Figure 17. Human Papillomavirus (HPV) Image Figure 18. Hepatitis E Virus (HEV) Image Figure 19. Hepatitis B Virus (HBV) Image Figure 20. Other Image Figure 21. Global Virus like Particle (VLP) Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Virus like Particle (VLP) Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Virus like Particle (VLP) Vaccines Sales Volume Share by Application (2021-2032) Figure 24. Global Virus like Particle (VLP) Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Virus like Particle (VLP) Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Virus like Particle (VLP) Vaccines Sales Value Share by Application (2021-2032) Figure 27. Global Virus like Particle (VLP) Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Virus like Particle (VLP) Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Virus like Particle (VLP) Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Virus like Particle (VLP) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. North America Virus like Particle (VLP) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Virus like Particle (VLP) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Virus like Particle (VLP) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Virus like Particle (VLP) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Virus like Particle (VLP) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. South America Virus like Particle (VLP) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Virus like Particle (VLP) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Virus like Particle (VLP) Vaccines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Virus like Particle (VLP) Vaccines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Prophylactic Vaccine
  • Therapeutic Vaccine
Applications
  • Human Papillomavirus (HPV)
  • Hepatitis E Virus (HEV)
  • Hepatitis B Virus (HBV)
  • Other
Companies covered
  • WuXi Biologics
  • Junshi Biosciences
  • Luye Pharma Group
  • Chengdu Kanghua Biological Products Co., Ltd.
  • Shanghai Bovax Biotechnology Co., Ltd.
  • VBI Vaccines Inc
  • Premas Biotech
  • Creative Diagnostics
  • Creative Biostructure
  • Coriolis
  • Charles River Laboratories
  • BioAgilytix
  • AstraZeneca Group (Icosavax)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Virus like Particle (VLP) Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Virus like Particle (VLP) Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Virus like Particle (VLP) Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Virus like Particle (VLP) Vaccines Market Dynamics
  1. 2.1 Virus like Particle (VLP) Vaccines Industry Trends
  2. 2.2 Virus like Particle (VLP) Vaccines Industry Drivers
  3. 2.3 Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges
  4. 2.4 Virus like Particle (VLP) Vaccines Industry Restraints
3 Virus like Particle (VLP) Vaccines Market by Company
  1. 3.1 Global Virus like Particle (VLP) Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Virus like Particle (VLP) Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Virus like Particle (VLP) Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Virus like Particle (VLP) Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Virus like Particle (VLP) Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Virus like Particle (VLP) Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Virus like Particle (VLP) Vaccines Company Product Type and Application
  8. 3.8 Global Virus like Particle (VLP) Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Virus like Particle (VLP) Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Virus like Particle (VLP) Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Virus like Particle (VLP) Vaccines Market by Type
  1. 4.1 Virus like Particle (VLP) Vaccines Type Introduction
  2. 4.1.1 Prophylactic Vaccine
  3. 4.1.2 Therapeutic Vaccine
  4. 4.2 Global Virus like Particle (VLP) Vaccines Sales Volume by Type
  5. 4.2.1 Global Virus like Particle (VLP) Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Virus like Particle (VLP) Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Virus like Particle (VLP) Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Virus like Particle (VLP) Vaccines Sales Value by Type
  9. 4.3.1 Global Virus like Particle (VLP) Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Virus like Particle (VLP) Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Virus like Particle (VLP) Vaccines Sales Value Share by Type (2021-2032)
5 Virus like Particle (VLP) Vaccines Market by Application
  1. 5.1 Virus like Particle (VLP) Vaccines Application Introduction
  2. 5.1.1 Human Papillomavirus (HPV)
  3. 5.1.2 Hepatitis E Virus (HEV)
  4. 5.1.3 Hepatitis B Virus (HBV)
  5. 5.1.4 Other
  6. 5.2 Global Virus like Particle (VLP) Vaccines Sales Volume by Application
  7. 5.2.1 Global Virus like Particle (VLP) Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Virus like Particle (VLP) Vaccines Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Virus like Particle (VLP) Vaccines Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Virus like Particle (VLP) Vaccines Sales Value by Application
  11. 5.3.1 Global Virus like Particle (VLP) Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Virus like Particle (VLP) Vaccines Sales Value by Application (2021-2032)
  13. 5.3.3 Global Virus like Particle (VLP) Vaccines Sales Value Share by Application (2021-2032)
6 Virus like Particle (VLP) Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Virus like Particle (VLP) Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Virus like Particle (VLP) Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Virus like Particle (VLP) Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Virus like Particle (VLP) Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Virus like Particle (VLP) Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Virus like Particle (VLP) Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Virus like Particle (VLP) Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Virus like Particle (VLP) Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Virus like Particle (VLP) Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Virus like Particle (VLP) Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Virus like Particle (VLP) Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Virus like Particle (VLP) Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Virus like Particle (VLP) Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Virus like Particle (VLP) Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Virus like Particle (VLP) Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Virus like Particle (VLP) Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Virus like Particle (VLP) Vaccines Sales Value Share by Country, 2025 VS 2032
7 Virus like Particle (VLP) Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Virus like Particle (VLP) Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Virus like Particle (VLP) Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Virus like Particle (VLP) Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Virus like Particle (VLP) Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Virus like Particle (VLP) Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Virus like Particle (VLP) Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Virus like Particle (VLP) Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Virus like Particle (VLP) Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Virus like Particle (VLP) Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Virus like Particle (VLP) Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 WuXi Biologics
  2. 8.1.1 WuXi Biologics Company Information
  3. 8.1.2 WuXi Biologics Business Overview
  4. 8.1.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio
  6. 8.1.5 WuXi Biologics Recent Developments
  7. 8.2 Junshi Biosciences
  8. 8.2.1 Junshi Biosciences Company Information
  9. 8.2.2 Junshi Biosciences Business Overview
  10. 8.2.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio
  12. 8.2.5 Junshi Biosciences Recent Developments
  13. 8.3 Luye Pharma Group
  14. 8.3.1 Luye Pharma Group Company Information
  15. 8.3.2 Luye Pharma Group Business Overview
  16. 8.3.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio
  18. 8.3.5 Luye Pharma Group Recent Developments
  19. 8.4 Chengdu Kanghua Biological Products Co., Ltd.
  20. 8.4.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
  21. 8.4.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
  22. 8.4.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
  24. 8.4.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
  25. 8.5 Shanghai Bovax Biotechnology Co., Ltd.
  26. 8.5.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
  27. 8.5.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
  28. 8.5.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
  30. 8.5.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
  31. 8.6 VBI Vaccines Inc
  32. 8.6.1 VBI Vaccines Inc Company Information
  33. 8.6.2 VBI Vaccines Inc Business Overview
  34. 8.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio
  36. 8.6.5 VBI Vaccines Inc Recent Developments
  37. 8.7 Premas Biotech
  38. 8.7.1 Premas Biotech Company Information
  39. 8.7.2 Premas Biotech Business Overview
  40. 8.7.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio
  42. 8.7.5 Premas Biotech Recent Developments
  43. 8.8 Creative Diagnostics
  44. 8.8.1 Creative Diagnostics Company Information
  45. 8.8.2 Creative Diagnostics Business Overview
  46. 8.8.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio
  48. 8.8.5 Creative Diagnostics Recent Developments
  49. 8.9 Creative Biostructure
  50. 8.9.1 Creative Biostructure Company Information
  51. 8.9.2 Creative Biostructure Business Overview
  52. 8.9.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio
  54. 8.9.5 Creative Biostructure Recent Developments
  55. 8.10 Coriolis
  56. 8.10.1 Coriolis Company Information
  57. 8.10.2 Coriolis Business Overview
  58. 8.10.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio
  60. 8.10.5 Coriolis Recent Developments
  61. 8.11 Charles River Laboratories
  62. 8.11.1 Charles River Laboratories Company Information
  63. 8.11.2 Charles River Laboratories Business Overview
  64. 8.11.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio
  66. 8.11.5 Charles River Laboratories Recent Developments
  67. 8.12 BioAgilytix
  68. 8.12.1 BioAgilytix Company Information
  69. 8.12.2 BioAgilytix Business Overview
  70. 8.12.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio
  72. 8.12.5 BioAgilytix Recent Developments
  73. 8.13 AstraZeneca Group (Icosavax)
  74. 8.13.1 AstraZeneca Group (Icosavax) Company Information
  75. 8.13.2 AstraZeneca Group (Icosavax) Business Overview
  76. 8.13.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio
  78. 8.13.5 AstraZeneca Group (Icosavax) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Virus like Particle (VLP) Vaccines Value Chain Analysis
  2. 9.1.1 Virus like Particle (VLP) Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Virus like Particle (VLP) Vaccines Sales Mode & Process
  6. 9.2 Virus like Particle (VLP) Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Virus like Particle (VLP) Vaccines Distributors
  9. 9.2.3 Virus like Particle (VLP) Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst